Tazverik Receives FDA Approval as First Treatment Specifically for Metastatic or Locally Advanced Epithelioid Sarcoma

Web Exclusives - FDA Updates, In the News, Sarcoma

On January 23, 2020, the FDA granted accelerated approval to tazemetostat (Tazverik; Epizyme), a methyltransferase inhibitor, for the treatment of metastatic or locally advanced epithelioid sarcoma in adults and pediatric patients aged ≥16 years who are not eligible for complete resection.

“For people with epithelioid sarcoma, an aggressive life-threatening cancer that affects young adults, having new treatment options can offer much-needed hope,” said Denise Reinke, MS, NP, MBA, President and Chief Executive Officer, Sarcoma Alliance for Research Through Collaboration, and Co-Founder, Sarcoma Coalition, in a press release.

This approval was based on improvements in overall response rate (ORR) and duration of response (DOR) in a phase 2 clinical trial. Verification and description of clinical benefit in a confirmatory clinical trial(s) may be necessary for continued approval of tazemetostat for this indication.

Key Takeaways:

  • The efficacy of tazemetostat was evaluated in a phase 2, open-label, single-arm cohort (Cohort 5) of a multicenter study in patients with histologically confirmed, metastatic, or locally advanced epithelioid sarcoma. Patients were required to have INI1 protein loss, detected using local tests, and an Eastern Cooperative Oncology Group performance status of 0-2.
  • Patients received tazemetostat 800 mg orally twice daily until disease progression or unacceptable toxicity. Tumor response assessments were performed every 8 weeks. The major efficacy outcome measures were confirmed ORR according to Response Evaluation Criteria in Solid Tumors v1.1 as assessed by blinded independent central review and DOR. Median duration of follow-up was 14 months (range, 0.4-31).
  • Of the 62 patients treated in Cohort 5, the ORR was 15%, with 1.6% achieving a complete response, and 13% achieving a partial response. Among the responders, 67% had a DOR ≥6 months.
  • The most common (≥20%) adverse reactions were pain, fatigue, nausea, decreased appetite, vomiting, and constipation.
  • Tazemetostat increases the risk for secondary malignancies, such as T-cell lymphoma, myelodysplastic syndrome, and acute myeloid leukemia.
  • Tazemetostat can cause fetal harm. Patients should be advised of potential risk to a fetus and to use effective nonhormonal contraception.
Related Items
FDA News: April 1, 2022, and May 27, 2022
TOP - July 2022 Vol 15, No 4 published on July 20, 2022 in FDA Updates
FDA NEWS: February 28, 2022 to March 31, 2022
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in FDA Updates
FDA NEWS: January 10, 2022, and January 25, 2022
TOP - March 2022 Vol 15, No 2 published on March 16, 2022 in FDA Updates
FDA NEWS: November 29, 2021, and December 15, 2021
TOP - January 2022 Vol 15, No 1 – Online Only published on January 20, 2022 in FDA Updates
FDA NEWS: August 13, 2021 to September 22, 2021
TOP - November 2021 Vol 14, No 7 published on November 10, 2021 in FDA Updates
FDA Issues Revised Final Guidance on Biosimilar Development and the BPCI Act
TOP - October 2021 Vol 14, No 6 | Biosimilars published on November 5, 2021 in FDA Updates, Biosimilars
FDA NEWS: June 30, 2021, and July 26, 2021
TOP - September 2021 Vol 14, No 5 published on September 7, 2021 in FDA Updates
FDA NEWS: May 5, 2021 to May 28, 2021
TOP - July 2021 Vol 14, No 4 published on July 20, 2021 in FDA Updates
FDA NEWS: April 13, 2021 to April 23, 2021
TOP - May 2021 Vol 14, No 3 published on May 14, 2021 in FDA Updates
FDA NEWS: February 5, 2021 to February 22, 2021
TOP - March 2021 Vol 14, No 2 published on March 11, 2021 in FDA Updates
Last modified: July 22, 2021